Kaplan Meier analysis showed patients with high IASLC/ATS/ERS classification of risk groups (p=0.037), poor differentiation (p=0.001), lymph node metastasis (p=0.008), abnormal CEA (p=0.045), high CDC25a expression (p=0.004), high YBX1 expression (p=0.044) or uplifted TNM stage (p<0.001) had poorer survival outcome by log-rank test (Table 3 and Figure 3B-3E). The gene discussed is YBX1; the disease is metastatic malignant neoplasm in the lymph nodes.